Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 2 (2005), Issue 4 (April)

1. Paraneoplastic recurrent multifocal encephalitis presenting with epilepsia partialis continua.
   J Neurooncol, 72(1): 63-6. [Abstract] [Full-text]
2. USCAP Specialty Conference: case 1-type I pleuropulmonary blastoma.
   Pediatr Dev Pathol, 8(1): 77-84. [Abstract] [Full-text]
3. Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer.
   J Clin Oncol, 23(10): 2136-44. [Abstract] [Full-text]
4. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
   Cancer Res, 65(7): 2854-60. [Abstract] [Full-text]
5. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers.
   Cancer Res, 65(7): 2795-803. [Abstract] [Full-text]
6. p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors.
   Cancer Res, 65(7): 2583-7. [Abstract] [Full-text]
7. Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism.
   Hum Genet, 116(5): 354-60. [Abstract] [Full-text]
8. Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer.
   Cancer Lett, 221(2): 185-90. [Abstract] [Full-text]
9. 'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility.
   Cancer Lett, 221(2): 177-83. [Abstract] [Full-text]
10. Anti-alpha-enolase antibodies in cancer-associated retinopathy with small cell carcinoma of the lung.
    Am J Ophthalmol, 139(4): 746-7. [Abstract] [Full-text]
11. 'Successful' chemo- and radiotherapy prior to radical cystectomy does not necessarily correlate with clinical course in small cell carcinoma of the bladder.
    Urol Int, 74(3): 286-8. [Abstract] [Full-text]
12. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
    J Natl Cancer Inst, 97(7): 499-506. [Abstract] [Full-text]
13. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers.
    Br J Cancer, 92(7): 1231-9. [Abstract] [Full-text]
14. Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.
    Chemotherapy, 51(1): 32-9. [Abstract] [Full-text]
15. Familial aggregation of lung cancer in a high incidence area in China.
    Br J Cancer, 92(7): 1321-5. [Abstract] [Full-text]
16. Lung metastasis of thymoma manifesting as myasthenia gravis 12 years after thymomectomy: report of a case.
    Surg Today, 35(4): 309-12. [Abstract] [Full-text]
17. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer.
    Clin Cancer Res, 11(7): 2502-9. [Abstract] [Full-text]
18. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer.
    Clin Cancer Res, 11(7): 2466-70. [Abstract] [Full-text]
19. Impact of IMRT and leaf width on stereotactic body radiotherapy of liver and lung lesions.
    Int J Radiat Oncol Biol Phys, 61(5): 1572-81. [Abstract] [Full-text]
20. Treatment planning of stereotactic radiotherapy for solitary lung tumor.
    Int J Radiat Oncol Biol Phys, 61(5): 1565-71. [Abstract] [Full-text]
21. Four-dimensional image-based treatment planning: Target volume segmentation and dose calculation in the presence of respiratory motion.
    Int J Radiat Oncol Biol Phys, 61(5): 1535-50. [Abstract] [Full-text]
22. Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy.
    Int J Radiat Oncol Biol Phys, 61(5): 1355-63. [Abstract] [Full-text]
23. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
    J Clin Oncol, 23(11): 2556-68. [Abstract] [Full-text]
24. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
    J Clin Oncol, 23(11): 2544-55. [Abstract] [Full-text]
25. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
    J Clin Oncol, 23(11): 2513-20. [Abstract] [Full-text]
26. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    J Clin Oncol, 23(11): 2493-501. [Abstract] [Full-text]
27. Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.
    J Zhejiang Univ Sci B, 6(5): 446-50. [Abstract] [Full-text]
28. Border between N1 and N2 stations in lung carcinoma: lessons from lymph node metastatic patterns of lower lobe tumors.
    J Thorac Cardiovasc Surg, 129(4): 825-30. [Abstract] [Full-text]
29. Large-cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide.
    J Thorac Cardiovasc Surg, 129(4): 819-24. [Abstract] [Full-text]
30. Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study.
    J Thorac Cardiovasc Surg, 129(4): 813-8. [Abstract] [Full-text]
31. Surgical resection for lung cancer with infiltration of the thoracic aorta.
    J Thorac Cardiovasc Surg, 129(4): 804-8. [Abstract] [Full-text]
32. Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.
    Oncologist, 10(4): 282-91. [Abstract] [Full-text]
33. Cardiopulmonary exercise tests and lung cancer surgical outcome.
    Chest, 127(4): 1159-65. [Abstract] [Full-text]
34. Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival.
    Chest, 127(4): 1152-8. [Abstract] [Full-text]
35. Como international conference position statement: lung cancer screening for early diagnosis 5 years after the 1998 Varese conference.
    Chest, 127(4): 1146-51. [Abstract] [Full-text]
36. Lung cancer detection in patients with airflow obstruction identified in a primary care outpatient practice.
    Chest, 127(4): 1140-5. [Abstract] [Full-text]
37. Stage of lung cancer in relation to its size: part 2. Evidence.
    Chest, 127(4): 1136-9. [Abstract] [Full-text]
38. Is the urban excess in lung cancer in Scotland explained by patterns of smoking?
    Soc Sci Med, 60(12): 2833-43. [Abstract] [Full-text]
39. Functional analysis of cells obtained from bronchoalveolar lavage fluid (BALF) of lung cancer patients.
    Life Sci, 76(25): 2945-51. [Abstract] [Full-text]
40. Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis.
    Cancer Sci, 96(4): 227-31. [Abstract] [Full-text]
41. Intraabdominal desmoplastic small round cell tumour.
    Pediatr Surg Int, 21(4): 279-81. [Abstract] [Full-text]
42. Human insulin-like growth factor-IA expression in transgenic mice promotes adenomatous hyperplasia but not pulmonary fibrosis.
    Am J Physiol Lung Cell Mol Physiol, 288(5): L805-12. [Abstract] [Full-text]
43. Expression of matrix metalloproteinase-9 in pleural effusions of tuberculosis and lung cancer.
    Respiration, 72(2): 166-75. [Abstract] [Full-text]
44. TP53 mutation spectrum in lung cancer is not different in women and men.
    Cancer Epidemiol Biomarkers Prev, 14(4): 1031-3. [Abstract] [Full-text]
45. Safety and efficacy of weekly oral oltipraz in chronic smokers.
    Cancer Epidemiol Biomarkers Prev, 14(4): 892-9. [Abstract] [Full-text]
46. Chlamydia pneumoniae and lung cancer: epidemiologic evidence.
    Cancer Epidemiol Biomarkers Prev, 14(4): 773-8. [Abstract] [Full-text]
47. K-ras mutations in lung tumors from p53 mutant mice exposed to cigarette smoke.
    Exp Lung Res, 31(2): 271-81. [Abstract] [Full-text]
48. A database of single-nucleotide polymorphisms and a genotyping microarray for genetic epidemiology of lung cancer.
    Exp Lung Res, 31(2): 223-58. [Abstract] [Full-text]
49. Pooled analysis on metabolic gene polymorphisms and lung cancer.
    Exp Lung Res, 31(2): 217-22. [Abstract] [Full-text]
50. Familial risk for lung cancer by histology and age of onset: evidence for recessive inheritance.
    Exp Lung Res, 31(2): 205-15. [Abstract] [Full-text]
51. Identification of genetic polymorphisms through comparative DNA sequence analysis on the K-ras gene: implications for lung tumor susceptibility.
    Exp Lung Res, 31(2): 165-77. [Abstract] [Full-text]
52. Chemoprevention: mouse colon and lung tumor bioassay and modulation of DNA methylation as a biomarker.
    Exp Lung Res, 31(2): 145-63. [Abstract] [Full-text]
53. Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer.
    Respir Med, 99(5): 559-65. [Abstract] [Full-text]
54. A systematic nerve-sparing radical hysterectomy technique in invasive cervical cancer for preserving postsurgical bladder function.
    Int J Gynecol Cancer, 15(2): 389-97. [Abstract] [Full-text]
55. Epstein-Barr virus plays little role in cervical carcinogenesis in Korean women.
    Int J Gynecol Cancer, 15(2): 312-8. [Abstract] [Full-text]
56. Small-cell carcinoma of the uterine cervix: a clinicopathologic study of 11 cases.
    Int J Gynecol Cancer, 15(2): 295-300. [Abstract] [Full-text]
57. Cancer, Medicaid enrollment, and survival disparities.
    Cancer, 103(8): 1712-8. [Abstract] [Full-text]
58. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Cancer, 103(8): 1676-84. [Abstract] [Full-text]
59. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
    Cancer, 103(8): 1670-5. [Abstract] [Full-text]
60. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.
    Hum Mol Genet, 14(8): 997-1007. [Abstract] [Full-text]
61. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma.
    Cancer, 103(8): 1685-92. [Abstract] [Full-text]
62. DNA repair gene XPC genotypes/haplotypes and risk of lung cancer in a Chinese population.
    Int J Cancer, 115(3): 478-83. [Abstract] [Full-text]
63. Sheep retrovirus structural protein induces lung tumours.
    Nature, 434(7035): 904-7. [Abstract] [Full-text]
64. Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy.
    Cancer Detect Prev, 29(2): 181-8. [Abstract] [Full-text]
65. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
    Cancer Detect Prev, 29(2): 175-80. [Abstract] [Full-text]
66. Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy.
    Lung Cancer, 48(2): 281-9. [Abstract] [Full-text]
67. Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials.
    Lung Cancer, 48(2): 275-80. [Abstract] [Full-text]
68. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
    Lung Cancer, 48(2): 267-73. [Abstract] [Full-text]
69. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Lung Cancer, 48(2): 251-61. [Abstract] [Full-text]
70. Transesophageal endoscopic ultrasound/fine-needle aspiration diagnosis of a malignant adrenal gland in a patient with non-small cell lung cancer and a negative CT scan.
    Lung Cancer, 48(2): 247-9. [Abstract] [Full-text]
71. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.
    Lung Cancer, 48(2): 241-6. [Abstract] [Full-text]
72. Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung.
    Lung Cancer, 48(2): 233-40. [Abstract] [Full-text]
73. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer.
    Lung Cancer, 48(2): 223-31. [Abstract] [Full-text]
74. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
    Lung Cancer, 48(2): 217-21. [Abstract] [Full-text]
75. Adenovirus-uteroglobin suppresses COX-2 expression via inhibition of NF-kappaB activity in lung cancer cells.
    Lung Cancer, 48(2): 201-9. [Abstract] [Full-text]
76. Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway.
    Lung Cancer, 48(2): 187-99. [Abstract] [Full-text]
77. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Lung Cancer, 48(2): 171-85. [Abstract] [Full-text]
78. The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer.
    Oncogene, 24(16): 2735-8. [Abstract] [Full-text]
79. Solitary pulmonary nodule diagnosis on CT: results of an observer study.
    Acad Radiol, 12(4): 496-501. [Abstract] [Full-text]
80. A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein.
    Cancer Gene Ther, 12(5): 497-508. [Abstract] [Full-text]
81. C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis.
    Cancer Res, 65(8): 3374-9. [Abstract] [Full-text]
82. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Cancer Res, 65(8): 3328-35. [Abstract] [Full-text]
83. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
    Cancer Res, 65(8): 3226-35. [Abstract] [Full-text]
84. Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung.
    Cancer Res, 65(8): 3063-71. [Abstract] [Full-text]
85. Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment Of Cancer Therapy-Lung scale.
    Hematol Oncol Clin North Am, 19(2): 389-420, viii. [Abstract] [Full-text]
86. Supportive care in lung cancer.
    Hematol Oncol Clin North Am, 19(2): 369-87, vii. [Abstract] [Full-text]
87. Novel therapies in lung cancer.
    Hematol Oncol Clin North Am, 19(2): 343-67, vii. [Abstract] [Full-text]
88. Combined chemoradiotherapy in small cell lung cancer.
    Hematol Oncol Clin North Am, 19(2): 321-42, vii. [Abstract] [Full-text]
89. The role of surgery in stage IIIA non-small cell lung cancer.
    Hematol Oncol Clin North Am, 19(2): 303-19, vi-vii. [Abstract] [Full-text]
90. Postoperative radiation therapy for patients who have resected non-small cell lung cancer.
    Hematol Oncol Clin North Am, 19(2): 283-302, vi. [Abstract] [Full-text]
91. Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances.
    Hematol Oncol Clin North Am, 19(2): 263-81, vi. [Abstract] [Full-text]
92. Nonsurgical therapy for stages I and II non-small cell lung cancer.
    Hematol Oncol Clin North Am, 19(2): 237-61, v-vi. [Abstract] [Full-text]
93. Clinical evaluation and staging of patients who have lung cancer.
    Hematol Oncol Clin North Am, 19(2): 219-35, v. [Abstract] [Full-text]
94. Lung cancer screening.
    Hematol Oncol Clin North Am, 19(2): 209-17, v. [Abstract] [Full-text]
95. An approach to investigating the importance of high potency polycyclic aromatic hydrocarbons (PAHs) in the induction of lung cancer by air pollution.
    Food Chem Toxicol, 43(7): 1103-16. [Abstract] [Full-text]
96. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
    J Clin Oncol, 23(12): 2831-9. [Abstract] [Full-text]
97. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
    Clin Cancer Res, 11(8): 3032-7. [Abstract] [Full-text]
98. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Clin Cancer Res, 11(8): 3017-24. [Abstract] [Full-text]
99. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.
    Clin Cancer Res, 11(8): 2954-61. [Abstract] [Full-text]
100. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer.
     Clin Cancer Res, 11(8): 2930-6. [Abstract] [Full-text]
101. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
     Clin Cancer Res, 11(8): 2924-9. [Abstract] [Full-text]
102. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy.
     Clin Cancer Res, 11(8): 2894-8. [Abstract] [Full-text]
103. Lack of telomerase activity in lung carcinoids is dependent on human telomerase reverse transcriptase transcription and alternative splicing and is associated with long telomeres.
     Clin Cancer Res, 11(8): 2832-9. [Abstract] [Full-text]
104. Combinations of polymorphisms in XPD, XPC and XPA in relation to risk of lung cancer.
     Cancer Lett, 222(1): 67-74. [Abstract] [Full-text]
105. Wnt signaling in lung cancer.
     Cancer Lett, 222(1): 1-10. [Abstract] [Full-text]
106. Cancer pattern among hypertensive patients in North Karelia, Finland.
     J Hum Hypertens, 19(5): 373-9. [Abstract] [Full-text]
107. Cerebellar haemorrhage and tension pneumocephalus after resection of a Pancoast tumour.
     Acta Neurochir (Wien), 147(5): 561-4;discussion 564. [Abstract] [Full-text]
108. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study.
     J Natl Cancer Inst, 97(8): 567-76. [Abstract] [Full-text]
109. Experimental verification of lung dose with radiochromic film: comparison with Monte Carlo simulations and commercially available treatment planning systems.
     Phys Med Biol, 50(9): 2055-69. [Abstract] [Full-text]
110. Mesothelioma in household members of asbestos-exposed workers: 32 United States cases since 1990.
     Am J Ind Med, 47(5): 458-62. [Abstract] [Full-text]
111. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
     Ann Oncol, 16(5): 762-6. [Abstract] [Full-text]
112. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
     Ann Oncol, 16(5): 780-5. [Abstract] [Full-text]
113. Three Mile Island epidemiologic radiation dose assessment revisited: 25 years after the accident.
     Radiat Prot Dosimetry, 113(2): 214-7. [Abstract] [Full-text]
114. Are radon gas measurements adequate for epidemiological studies and case control studies of radon-induced lung cancer?
     Radiat Prot Dosimetry, 113(2): 233-5. [Abstract] [Full-text]
115. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small cell lung cancer.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
116. Postoperative radiotherapy for non-small cell lung cancer.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
117. Tobacco smoke-induced lung tumorigenesis in mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf.
     Oncogene, 24(18): 3042-9. [Abstract] [Full-text]
118. Case report: pulmonary blastoma: presentation of two atypical cases and review of the literature.
     Br J Radiol, 78(929): 437-40. [Abstract] [Full-text]
119. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.
     Br J Radiol, 78(929): 428-32. [Abstract] [Full-text]
120. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812).
     Jpn J Clin Oncol, 35(4): 195-201. [Abstract] [Full-text]
121. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
     Jpn J Clin Oncol, 35(4): 188-94. [Abstract] [Full-text]
122. A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.
     Jpn J Clin Oncol, 35(4): 181-7. [Abstract] [Full-text]
123. Trends in lung cancer mortality among young adults in Japan.
     Jpn J Clin Oncol, 35(4): 177-80. [Abstract] [Full-text]
124. Outcome following radiotherapy for loco-regionally recurrent non-small cell lung cancer.
     Australas Radiol, 49(2): 108-12. [Abstract] [Full-text]
125. Genomic and gene expression profiling of minute alterations of chromosome arm 1p in small-cell lung carcinoma cells.
     Br J Cancer, 92(8): 1553-60. [Abstract] [Full-text]
126. Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer.
     Acta Oncol, 44(1): 75-9. [Abstract] [Full-text]
127. Simultaneous double video mediastinoscopy and video mediastinotomy--a step forward.
     Eur J Cardiothorac Surg, 27(5): 920-2. [Abstract] [Full-text]
128. Metachronous adrenal masses in resected non-small cell lung cancer patients: therapeutic implications of laparoscopic adrenalectomy.
     Eur J Cardiothorac Surg, 27(5): 753-6. [Abstract] [Full-text]
129. Assessment of node dissection for clinical stage I primary lung cancer by VATS.
     Eur J Cardiothorac Surg, 27(5): 745-52. [Abstract] [Full-text]
130. Imaging of metastatic disease to the thorax.
     Radiol Clin North Am, 43(3): 481-95, vii. [Abstract] [Full-text]
131. Imaging of non-small cell lung cancer.
     Radiol Clin North Am, 43(3): 467-80, vii. [Abstract] [Full-text]
132. Radiologic evaluation of the solitary pulmonary nodule.
     Radiol Clin North Am, 43(3): 459-65, vii. [Abstract] [Full-text]
133. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis.
     Cancer, 103(9): 1865-73. [Abstract] [Full-text]
134. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
     Int J Cancer, 115(4): 545-55. [Abstract] [Full-text]
135. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
     Int J Cancer, 115(4): 575-81. [Abstract] [Full-text]
136. Pas1 haplotype-dependent genetic predisposition to lung tumorigenesis in rodents: a meta-analysis.
     Carcinogenesis, 26(5): 875-82. [Abstract] [Full-text]
137. Which patients with stage III non-small cell lung cancer should undergo surgical resection?
     Oncologist, 10(5): 335-44. [Abstract] [Full-text]
138. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
     Int J Radiat Oncol Biol Phys, 62(1): 76-81. [Abstract] [Full-text]
139. Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer?
     Int J Radiat Oncol Biol Phys, 62(1): 70-5. [Abstract] [Full-text]
140. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
     Cancer Chemother Pharmacol, 55(6): 552-8. [Abstract] [Full-text]
141. Thoracic non-rigid registration combining self-organizing maps and radial basis functions.
     Med Image Anal, 9(3): 237-54. [Abstract] [Full-text]
142. Regional differences of melphalan lung levels after isolated lung perfusion in the rat.
     J Surg Res, 125(2): 157-60. [Abstract] [Full-text]
143. Significance analysis of functional categories in gene expression studies: a structured permutation approach.
     Bioinformatics, 21(9): 1943-9. [Abstract] [Full-text]
144. Minor morphologic abnormalities of adrenal glands at CT: prognostic importance in patients with lung cancer.
     Radiology, 235(2): 517-22. [Abstract] [Full-text]
145. Acrokeratosis paraneoplastica: Bazex syndrome.
     J Eur Acad Dermatol Venereol, 19(3): 340-4. [Abstract] [Full-text]
146. Differentially expressed nucleolar TGF-beta1 target (DENTT) shows tissue-specific nuclear and cytoplasmic localization and increases TGF-beta1-responsive transcription in primates.
     Biochim Biophys Acta, 1728(3): 163-80. [Abstract] [Full-text]
147. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
     J Clin Oncol, 23(13): 3125-37. [Abstract] [Full-text]
148. Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer.
     J Clin Oncol, 23(13): 2962-70. [Abstract] [Full-text]
149. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group.
     J Clin Oncol, 23(13): 2955-61. [Abstract] [Full-text]
150. Asbestos, asbestosis, and lung cancer: a critical assessment of the epidemiological evidence.
     Thorax, 60(5): 433-6. [Abstract] [Full-text]
151. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
     J Clin Oncol, 23(13): 2926-36. [Abstract] [Full-text]
152. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
     J Clin Oncol, 23(13): 2937-45. [Abstract] [Full-text]
153. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
     J Clin Oncol, 23(13): 2946-54. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.